Targeted Oncology· @TargetedOnc · X·· 22 小时前评分70
正文 · 原文
Could PD-L1 selection be the real story in KEYNOTE-B49?
In CPS ≥10, PFS HR was 0.59 (median 7.5 vs 4.4 months).
Is this a clinically meaningful subgroup or an exploratory signal?
We need interaction testing, subgroup OS and patient-reported outcomes. #ESMO26
64 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源:Targeted Oncology · x.com
